Radiation Oncology | Links Medicus Content Curation & Alerts in Medicine

SR | Partial breast irradiation for breast cancer

3 Feb, 2023 | 14:06h | UTC

Partial Breast Irradiation for Breast Cancer – Agency for Healthcare Research and Quality

Perspective | Endocrine treatment for 5 years or radiation for 5 days for patients with early breast cancer older than 65 years

26 Jan, 2023 | 12:04h | UTC

Endocrine Treatment for 5 Years or Radiation for 5 Days for Patients With Early Breast Cancer Older Than 65 Years: Can We Do It Right? – Journal of Clinical Oncology

Commentary from the author on Twitter

🚨Hot off the press @JCO_ASCO: For decades we have been offering RT omission for early #bcsm patients, here we discuss how tides have changed and its time to omit hormonal therapy and treat with RT instead @TaghianAlphonse @MGHBreastOnc @LurieCancer

https://t.co/bqoeC1weYS

— George E. Naoum, MD, MMSCI (@George_E_Naoum) December 20, 2022

RCT | Effect of interval between neoadjuvant chemoradiotherapy and surgery on disease recurrence and survival in rectal cancer

20 Jan, 2023 | 14:19h | UTC

Effect of interval between neoadjuvant chemoradiotherapy and surgery on disease recurrence and survival in rectal cancer: long-term results of a randomized clinical trial – BJS Open

Commentary on Twitter

Single centre #RCT of surgery for T3/4 N+ #rectalcancer before or after 8 weeks of CRT

🧑‍🤝‍🧑350 patients
⚖️no difference locoregional recurrence
Distant mets more common in delayed group at 5yrs
DFS and OS similar#some4surgery @SEIQuirurgica @asgbi https://t.co/4evsKNKKK1 pic.twitter.com/CxI0GJdG56

— BJS Open (@BjsOpen) October 24, 2022

SR | Interventions for preventing and ameliorating cognitive deficits in adults treated with cranial irradiation

19 Jan, 2023 | 14:09h | UTC

Interventions for preventing and ameliorating cognitive deficits in adults treated with cranial irradiation – Cochrane Library

Summary: Interventions for preventing and ameliorating cognitive deficits in adults treated with cranial irradiation – Cochrane Library

RCT | MRI–guided vs. CT–guided stereotactic body radiotherapy for prostate cancer

15 Jan, 2023 | 20:05h | UTC

Magnetic Resonance Imaging–Guided vs Computed Tomography–Guided Stereotactic Body Radiotherapy for Prostate Cancer: The MIRAGE Randomized Clinical Trial – JAMA Oncology

News Release: MRI-guided radiotherapy produces fewer side effects and better quality of life for patients with localized prostate cancer – University of California

Commentary from the author on Twitter (thread – click for more)

Pleased to share the primary endpoint results of the randomized phase III MIRAGE trial evaluating whether aggressive margin reduction with MRI-guidance leads to reduced toxicity in the context of prostate SBRT, out today in @JAMAOncology https://t.co/5ZKElUR4uk (1/n)

— Amar Kishan (@AmarUKishan) January 12, 2023

RCT | Cosmetic results and side effects of accelerated partial-breast irradiation vs. whole-breast irradiation for low-risk invasive carcinoma of the breast

15 Jan, 2023 | 19:53h | UTC

Cosmetic Results and Side Effects of Accelerated Partial-Breast Irradiation Versus Whole-Breast Irradiation for Low-Risk Invasive Carcinoma of the Breast: The Randomized Phase III IRMA Trial – Journal of Clinical Oncology (link to abstract – $ for full-text)

Commentary from the author on Twitter

5yr results of the phase 3 #IRMAtrial: EBRT #APBI b.i.d. associated with slightly increased rate of moderate soft tissue and bone toxicity and a slightly inferior cosmesis, though overall toxicity was in an acceptable range @JCO_ASCO #BCSM @OncoAlert https://t.co/8LHE2ut3t2

— Bruno Meduri (@brunomeduri) January 9, 2023

RCT | High-dose once-daily thoracic radiotherapy in limited-stage small-cell lung cancer

15 Jan, 2023 | 19:51h | UTC

High-Dose Once-Daily Thoracic Radiotherapy in Limited-Stage Small-Cell Lung Cancer: CALGB 30610 (Alliance)/RTOG 0538 – Journal of Clinical Oncology (link to abstract – $ for full-text)

NCCN Guideline | Pediatric central nervous system cancers

12 Jan, 2023 | 13:11h | UTC

Pediatric Central Nervous System Cancers, Version 2.2023, NCCN Clinical Practice Guidelines in Oncology – Journal of the National Comprehensive Cancer Network

Editorial: ASCO Living Guidelines: The Next Frontier

Cohort Study | 5-year outcomes after stereotactic ablative body radiotherapy for primary renal cell carcinoma

11 Jan, 2023 | 14:10h | UTC

5-year outcomes after stereotactic ablative body radiotherapy for primary renal cell carcinoma: an individual patient data meta-analysis from IROCK (the International Radiosurgery Consortium of the Kidney) – The Lancet Oncology (link to abstract – $ for full-text)

Commentary from the author on Twitter (thread – click for more)

🧵1/ Wide adoption of SABR for primary #kidneycancer is limited by long-term data. Online today @TheLancetOncol; 5-yr outcomes in 190 patients. 5% local failure rates, 95% cancer-specific survival. Thanks @ElsevierConnect for 50-day link: #radonc #kcsm https://t.co/kCM8TraJE3

— Shankar Siva (@_ShankarSiva) November 16, 2022

RCT | Neoadjuvant chemotherapy with CAPOX vs. chemoradiation for locally advanced rectal cancer with uninvolved mesorectal fascia

10 Jan, 2023 | 14:09h | UTC

Neoadjuvant Chemotherapy with CAPOX versus Chemoradiation for Locally Advanced Rectal Cancer with Uninvolved Mesorectal Fascia (CONVERT): Initial Results of a Phase III Trial – Annals of Surgery

Post-trial follow-up | Radiotherapy vs. surgery of the axilla after a positive sentinel node in breast cancer.

14 Dec, 2022 | 14:42h | UTC

Radiotherapy or Surgery of the Axilla After a Positive Sentinel Node in Breast Cancer: 10-Year Results of the Randomized Controlled EORTC 10981-22023 AMAROS Trial – Journal of Clinical Oncology (link to abstract – $ for full-text)

Commentary: ART Preferred Over ALND in Sentinel Node-Positive Early Breast Cancer – Cancer Therapy Advisor

RCT | Mepitel film for the prevention of acute radiation dermatitis in breast cancer.

12 Dec, 2022 | 12:40h | UTC

Mepitel Film for the Prevention of Acute Radiation Dermatitis in Breast Cancer: A Randomized Multicenter Open-Label Phase III Trial – Journal of Clinical Oncology (link to abstract – $ for full-text)

Quick Guide for Radiation Oncologists | Everything you always wanted to know about sarcopenia but were afraid to ask.

21 Nov, 2022 | 14:29h | UTC

Everything You Always Wanted to Know about Sarcopenia but Were Afraid to Ask: A Quick Guide for Radiation Oncologists (impAct oF saRcopeniA In raDiotherapy: The AFRAID Project) – Current Oncology

RCT | Shortened course of radiation therapy safe and effective for men with high-risk prostate cancer.

11 Nov, 2022 | 13:55h | UTC

[News release – not published yet] Shortened course of radiation therapy safe and effective for men with high-risk prostate cancer – American Society for Radiation Oncology (ASTRO) Annual Meeting

Single-arm P2 study | Hypofractionated, 3-week, preoperative radiotherapy for patients with soft tissue sarcomas.

9 Nov, 2022 | 12:24h | UTC

Hypofractionated, 3-week, preoperative radiotherapy for patients with soft tissue sarcomas (HYPORT-STS): a single-centre, open-label, single-arm, phase 2 trial – The Lancet Oncology (link to abstract – $ for full-text)

News Release: Shorter course of radiation therapy yields comparable results for patients with non-metastatic soft tissue sarcoma – The University of Texas MD Anderson Cancer Center

Phase 2 RCT | Concurrent Bevacizumab and reirradiation vs. Bevacizumab alone as treatment for recurrent glioblastoma.

9 Nov, 2022 | 12:21h | UTC

NRG Oncology/RTOG1205: A Randomized Phase II Trial of Concurrent Bevacizumab and Reirradiation Versus Bevacizumab Alone as Treatment for Recurrent Glioblastoma – Journal of Clinical Oncology (link to abstract – $ for full-text)

Commentary: Bevacizumab Plus Reirradiation Improves PFS in Glioblastoma Multiforme – OncLive

SR | Efficacy and safety of stereotactic body radiotherapy for painful bone metastases.

8 Nov, 2022 | 12:00h | UTC

Efficacy and safety of stereotactic body radiotherapy for painful bone metastases: Evidence from randomized controlled trials – Frontiers in Oncology

Post-trial follow-up | Long-term outcomes with stereotactic radiosurgery vs. whole-brain RT for resected brain metastasis.

7 Nov, 2022 | 12:22h | UTC

Association of Long-term Outcomes With Stereotactic Radiosurgery vs Whole-Brain Radiotherapy for Resected Brain Metastasis: A Secondary Analysis of The N107C/CEC.3 (Alliance for Clinical Trials in Oncology/Canadian Cancer Trials Group) Randomized Clinical Trial – JAMA Oncology (link to abstract – $ for full-text)

Commentary: Survivors face less late cognitive deterioration after stereotactic radiosurgery than WBRT – medwire News

Original Study: Postoperative stereotactic radiosurgery compared with whole brain radiotherapy for resected metastatic brain disease (NCCTG N107C/CEC·3): a multicentre, randomised, controlled, phase 3 trial – The Lancet Oncology (link to abstract – $ for full-text)

Commentary on Twitter

In pts w limited brain mets after surgical resection, secondary analysis of rand phase 3 trial shows more patients declined significantly in 1 or more cognitive tests with whole brain radiation therapy (WBRT) vs stereotactic radiosurgery (SRS) https://t.co/6nSCO5kSpW #BTSM

— JAMA Oncology (@JAMAOnc) October 22, 2022

Cohort Study | Association of sinoatrial node radiation dose with atrial fibrillation and mortality in patients with lung cancer.

3 Nov, 2022 | 13:39h | UTC

Association of Sinoatrial Node Radiation Dose With Atrial Fibrillation and Mortality in Patients With Lung Cancer – JAMA Oncology (link to abstract – $ for full-text)

Commentaries:

Sinoatrial Node Radiation During CRT May Increase Risk of Atrial Fibrillation in SCLC and NSCLC – Cancer Network

Incidental sinoatrial node irradiation may increase AF risk in lung cancer – medwire News

Commentary on Twitter

Incidental irradiation to the sinoatrial node may cause new-onset #AtrialFibrillation & decrease overall survival in patients with #LungCancer receiving concurrent #chemoradiotherapy. https://t.co/hPVSnhp11R #RadOnc #LCSM

— JAMA Oncology (@JAMAOnc) September 27, 2022

[News Release] RCT | Shortened course of radiation therapy safe and effective for men with high-risk prostate cancer.

27 Oct, 2022 | 12:32h | UTC

News Release: Shortened course of radiation therapy safe and effective for men with high-risk prostate cancer – ASTRO Annual Meeting

Abstract: Conventional vs. Hypofractionated, Radiotherapy for High-Risk Prostate Cancer: 7-Year Outcomes of the Randomized, Non-Inferiority, Phase 3 PCS5 Trial – ASTRO Annual Meeting

Single-arm P2 study | Toxic effects of stereotactic ablative radiotherapy for up to 5 oligometastases in patients with cancer.

26 Oct, 2022 | 14:28h | UTC

Treatment With Stereotactic Ablative Radiotherapy for Up to 5 Oligometastases in Patients With Cancer: Primary Toxic Effect Results of the Nonrandomized Phase 2 SABR-5 Clinical Trial – JAMA Oncology (link to abstract – $ for full-text)

Commentary: Stereotactic Ablative Body Radiotherapy Produces Acceptable Toxic Effects in Patients With Cancer and Oligometastses – Cancer Network

Commentary on Twitter

Population-based phase 2 non-randomized trial of 381 pts w/oligometastatic or oligoprogressive disease & treated w/stereotactic ablative body radiotherapy (SABR) found rates of grade 2, 3,4, & 5 toxicities of 14.2%, 4.2%, 0%, & 0.3%, respectively. https://t.co/dDpdOEvNzk #RadOnc

— JAMA Oncology (@JAMAOnc) September 29, 2022

Phase 2 RCT | Nivolumab with or without Ipilimumab combined with stereotactic body radiotherapy for metastatic pancreatic cancer.

24 Oct, 2022 | 14:01h | UTC

Randomized Phase II Study of Nivolumab With or Without Ipilimumab Combined With Stereotactic Body Radiotherapy for Refractory Metastatic Pancreatic Cancer (CheckPAC) – Journal of Clinical Oncology (link to abstract – $ for full-text)

Commentary: SBRT Plus Nivolumab/Ipilimumab Yields Meaningful Activity in Metastatic Pancreatic Cancer – Cancer Network

Commentary on Twitter

Phase II CheckPAC Trial in refractory #PancreaticCancer
✅ 37.2% of pts achieved clinical benefit after stereotactic #RadiationTherapy in combination w/ nivolumab and ipilimumab
⛔ PD-L1 score was not associated with benefit

Read more: https://t.co/rxDnYvIUMl #JCO #PancSM pic.twitter.com/u7FfQEwN7a

— Journal of Clinical Oncology (@JCO_ASCO) May 9, 2022